134 related articles for article (PubMed ID: 37578465)
21. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
[TBL] [Abstract][Full Text] [Related]
22. Down-regulation of RCC1 sensitizes immunotherapy by up-regulating PD-L1 via p27
Zeng X; Zhong M; Yang Y; Wang Z; Zhu Y
J Cell Mol Med; 2021 Apr; 25(8):4136-4147. PubMed ID: 33630417
[TBL] [Abstract][Full Text] [Related]
23. TXNDC9 knockdown inhibits lung adenocarcinoma progression by targeting YWHAG.
Wang J; Pan X; Li J; Zhao J
Mol Med Rep; 2022 Jun; 25(6):. PubMed ID: 35485284
[TBL] [Abstract][Full Text] [Related]
24. MYC expression correlates with PD-L1 expression in non-small cell lung cancer.
Kim EY; Kim A; Kim SK; Chang YS
Lung Cancer; 2017 Aug; 110():63-67. PubMed ID: 28676221
[TBL] [Abstract][Full Text] [Related]
25. mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
Han K; Zhang Y
J Cancer Res Ther; 2019; 15(4):914-920. PubMed ID: 31436252
[TBL] [Abstract][Full Text] [Related]
26. Lung adenocarcinoma-intrinsic GBE1 signaling inhibits anti-tumor immunity.
Li L; Yang L; Cheng S; Fan Z; Shen Z; Xue W; Zheng Y; Li F; Wang D; Zhang K; Lian J; Wang D; Zhu Z; Zhao J; Zhang Y
Mol Cancer; 2019 Jun; 18(1):108. PubMed ID: 31221150
[TBL] [Abstract][Full Text] [Related]
27. EphA10 drives tumor progression and immune evasion by regulating the MAPK/ERK cascade in lung adenocarcinoma.
Zhao W; Liu L; Li X; Xu S
Int Immunopharmacol; 2022 Sep; 110():109031. PubMed ID: 35839564
[TBL] [Abstract][Full Text] [Related]
28. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
[TBL] [Abstract][Full Text] [Related]
29. FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma.
Zhou F; Wang X; Liu F; Meng Q; Yu Y
Int J Clin Oncol; 2020 Sep; 25(9):1612-1623. PubMed ID: 32430734
[TBL] [Abstract][Full Text] [Related]
30. MACC1 silencing inhibits cell proliferation and induces cell apoptosis of lung adenocarcinoma cells through the β-catenin pathway.
Guo L; Ou S; Ma X; Zhang S; Lai Y
Neoplasma; 2018; 65(4):552-560. PubMed ID: 29940751
[TBL] [Abstract][Full Text] [Related]
31. Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells.
Yuan LW; Jiang XM; Xu YL; Huang MY; Chen YC; Yu WB; Su MX; Ye ZH; Chen X; Wang Y; Lu JJ
Phytomedicine; 2021 Jan; 80():153394. PubMed ID: 33130472
[TBL] [Abstract][Full Text] [Related]
32. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.
Gao Y; Yang J; Cai Y; Fu S; Zhang N; Fu X; Li L
Int J Cancer; 2018 Aug; 143(4):931-943. PubMed ID: 29516506
[TBL] [Abstract][Full Text] [Related]
33. PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer.
Yu W; Hua Y; Qiu H; Hao J; Zou K; Li Z; Hu S; Guo P; Chen M; Sui S; Xiong Y; Li F; Lu J; Guo W; Luo G; Deng W
Cell Death Dis; 2020 Jul; 11(7):506. PubMed ID: 32632098
[TBL] [Abstract][Full Text] [Related]
34. AIM2 fosters lung adenocarcinoma immune escape by modulating PD-L1 expression in tumor-associated macrophages via JAK/STAT3.
Ye H; Yu W; Li Y; Bao X; Ni Y; Chen X; Sun Y; Chen A; Zhou W; Li J
Hum Vaccin Immunother; 2023 Dec; 19(3):2269790. PubMed ID: 37877820
[TBL] [Abstract][Full Text] [Related]
35. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC).
Hong W; Xue M; Jiang J; Zhang Y; Gao X
J Exp Clin Cancer Res; 2020 Aug; 39(1):149. PubMed ID: 32746878
[TBL] [Abstract][Full Text] [Related]
36. Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.
Zhou C; Che G; Zheng X; Qiu J; Xie Z; Cong Y; Pei X; Zhang H; Sun H; Ma H
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2663-2674. PubMed ID: 31541338
[TBL] [Abstract][Full Text] [Related]
37. Exosomes from M1-polarized macrophages promote apoptosis in lung adenocarcinoma via the miR-181a-5p/ETS1/STK16 axis.
Wang X; Huang R; Lu Z; Wang Z; Chen X; Huang D
Cancer Sci; 2022 Mar; 113(3):986-1001. PubMed ID: 35092121
[TBL] [Abstract][Full Text] [Related]
38. Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
Liu K; Luo J; Shao C; Ren Z; Sun S; Zhu Y; Zhou H; Jiang Z; Li X; Gu W; Xu Y; Qiang Y; Ren B; Xu L; Wu H; Shen Y
Med Sci Monit; 2020 Feb; 26():e920351. PubMed ID: 32108133
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of lncRNA A2M-AS1 inhibits cell growth and aggressiveness
Guo H; Li T; Peng C; Mao Q; Shen B; Shi M; Lu H; Xiao T; Yang A; Liu Y
Hum Exp Toxicol; 2022; 41():9603271221138971. PubMed ID: 36461613
[TBL] [Abstract][Full Text] [Related]
40. Lipid droplets-related Perilipin-3: potential immune checkpoint and oncogene in oral squamous cell carcinoma.
He Y; Liu L; Dong Y; Zhang X; Song Y; Jing Y; Ni Y; Wang Y; Wang Z; Ding L
Cancer Immunol Immunother; 2024 Mar; 73(5):78. PubMed ID: 38554152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
